Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Causal Role Found for Common Genetic Variant in Narcolepsy

By LabMedica International staff writers
Posted on 14 Jan 2014
An extraordinary association has been found between a specific gene variant related to the human leukocyte antigen immune system and narcolepsy. More...


Narcolepsy may be caused by an autoimmune response to an environmental trigger such as an infection and in people who are genetically susceptible to narcolepsy, the immune system may respond to the trigger by mistakenly attacking and destroying brain cells that make hypocretin, a hormone that helps promote alertness.

A large team of European scientists led by those at the University of Lausanne (Switzerland) performed a modified genome-wide association study involved 1,261 people with narcolepsy. This represented nearly 90% of European patients suffering from narcolepsy with cataplexy who have complete diagnostic work-up and DNA available. They were matched with 1,422 controls. High-resolution genotyping identified genetic variants including those in the human leukocyte antigen (HLA) system, which contains genes related to immune system function. Analysis was performed by logistic regression.

The investigators found that participants with the major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1) allele DQB1*06:02 were 251 times more likely to have narcolepsy with cataplexy than participants without the gene variant. This gene variant had a remarkably high negative predictive value of 99.32%, which means that nearly 100% of narcolepsy with cataplexy patients are DQB1*06:02 positive. Four other DQB1 alleles provided protection against narcolepsy, strongly supporting a causal role for DQB1 in narcolepsy. They suggested that high-resolution genotyping could play a valuable role in diagnosing patients suspected of having narcolepsy and evaluating at-risk populations.

Mehdi Tafti, PhD, the lead author and a professor in the Center for Integrative Genomics, said, “For the first time we have tested the HLA association all over Europe. This almost 100% association with HLA is somehow unique to narcolepsy and suggests a causal implication.” People with narcolepsy experience repeated daily episodes of an irrepressible need to sleep or lapses into sleep, which may occur as sudden, irresistible sleep "attacks." Another common symptom of narcolepsy is cataplexy, which involves sudden muscle weakness caused by strong emotions such as laughter. The study was published in January 2014 issue of the journal SLEEP.

Related Links:

University of Lausanne



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image: The proposed immunoassay uses ALZpath’s pTau217 antibody to detect Alzheimer’s disease biology in blood, supporting the growing role of blood-based biomarkers in clinical care (Photo courtesy of Shutterstock)

Agreement Supports pTau217-Based Alzheimer’s Blood Test Development

As disease-modifying therapies for Alzheimer’s disease expand, accessible diagnostics are increasingly needed to identify patients earlier. Current confirmatory methods, including PET imaging and cerebrospinal... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.